Daños neuropsicológicos asociados a los tratamientos quimioterapéuticos: una propuesta de evalucación

Referencias bibliográficas

• 1. Agra, y. V., Badía X. L. y gil, A. M. (1998). Instrumentos para la medición de la calidad de vida en los pacientes con cáncer. Medicina Clínica, 110, 703-708. [ Links ]
• 2. Ahles, T. A. y Saykin A. J. (2007). Candidate mechanisms for chemotherapy-induced cognitive changes. Nature Reviews Cancer, 7, 192-201. [ Links ]
• 3. Ahles, T. A., Saykin, A. J., Furstenberg, C. T., Cole, B., Mott, L. A., Skalla, K., Silberford, P. M. (2002). Neuropsychologic impact of standarddose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. Journal of Clinical Oncology, 20, 485-493. [ Links ]
• 4. Ahles, T. A., Saykin, A. J., McDonald, B. C., Furstenberg, C. T., Cole, B. F. y Hanscom, B.S. (2008). Cognitive function in breast cancer patients prior to adjuvant treatment. Breast Cancer Research and Treatment, 110, 143-152. [ Links ]
• 5. Ahles, T. A., Saykin A. J., McDonald, B. C., Li, y., Furstenberg, C. T., Hanscom, B. S. ... Kaufman, P. A. (2010). Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: Impact of age and cognitive reserve. Journal of Clinical Oncology, 28, 4434-4440. [ Links ]
• 6. Anderson-Hanley, C., Sherman, M. L., Riggs, R., Agocha, V. B. y Compas, B.E. (2003). Neuropsychological effects of treatments for adults with cancer: A meta-analysis and review of the literature. Journal of the International Neuropsychological Society, 9, 967-982. [ Links ]
• 7. Arrarás J. I., Illarramendi J. J. y Valerdi J. J. (1995) El cuestionario de Calidad de Vida de la EORTC, QLQ-C30. Estudio estadístico de validación con una muestra española. Revista de Psicología de la Salud, 7, 13-30. [ Links ]
• 8. Bender, C. M., Sereika, S.M., Berga, S. L., Vogel, V. g., Brufsky, A. M., Paraska K. K., Berga, S. L. (2006). Cognitive impairment associated with adjuvant therapy in breast cancer. Psycho-Oncology, 15, 422-430. [ Links ]
• 9. Brezden, C. B., Phillips, K. A., Abdolell, M., Bunston, T. y Tannock, I. F. (2000). Cognitive function in breast cancer patients receiving adjuvant chemotherapy. Journal of Clinical Oncology, 18, 2695-2701. [ Links ]
• 10. Brown, M. S., Stemmer, S. M., Simon, J. H., Stears, J. C., Jones, R. B., Cagnoni, P. J., Sheeder, J. L. (1998). White matter disease induced by highdose chemotherapy: Longitudinal study with MR imaging and proton spectroscopy. American Journal of Neuroradiology, 19, 217-221. [ Links ]
• 11. Boykoff, N., Moieni, M. y Karen, S. S. (2009). Confronting chemobrain: An in-depth look at survivors ´ reports of impact on work, social networks, and health care response. Journal Cancer Survivors, 3, 223-232. [ Links ]
• 12. Caro, I. y Ibáñez, E. (1992). Escala hospitalaria de ansiedad y depresión. Su utilidad práctica en Psicología de la salud. Boletín de Psicología, 36, 43-69. [ Links ]
• 13. Cimprich, B., So, H., Ronis, D.L. y Trask, C. (2005). Pre-treatment factors related to cognitive functioning in women newly diagnosed with breast cancer. Psycho-Oncology, 14, 70-78. [ Links ]
• 14. Cohen, J. (1977). Statistical power analysis for behavioural sciences (revised ed.). New york: Academic Press. [ Links ]
• 15. Comeche, M. I. M., Díaz, M. I. g. y Vallejo, M. A. P. (1995). Cuestionarios, inventarios y escalas: ansiedad, depresión y habilidades sociales (pp. 82-86). Madrid: Fundación Universidad-Empresa. [ Links ]
• 16. Correa, D. D. y Ahles, T. A. (2007). Late neuropsychologic effects of chemotherapy. Clinical Advances in Hematology & Oncology, 5, 987-988. [ Links ]
• 17 . van Dam, F. S.A. M., Schagen, S. B., Muller, M. J., Boogerd, W., Wall, E., Droogleever, M. E. F., Rodenhuis, S. (1998). Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: High-dose versus Standard-dose chemotherapy. Journal of the National Cancer Institute, 90, 210-218. [ Links ]
• 18. Downie, F. P., Mar Fan, H. g., Houédé-Tchen, N., yi, Q. y Tannock, I.F. (2006). Cognitive function, fatigue, and menopausal symptoms in breast cancer patients receiving adjuvant chemotherapy: Evaluation with patient interview after formal assessment. Psycho-Oncology, 15, 921-930. [ Links ]
• 19. Eberhardt, B. Dilger, S., Musial, F., Wedding, U., Weiss,T. y Miltner, N. H. R. (2006a). Short-term monitoring of cognitive functions before and during the first course of treatment. Journal of Cancer Research and Clinical Oncology, 132, 234-240. [ Links ]
• 20. Eberhardt, B., Dilger, S., Musial, F., Wedding, U., Weiss, T. y Miltner, W. H. R. (2006b). Mediumterm effects of chemotherapy in older cancer patients. Support Care in Cancer, 14, 216-222. [ Links ]
• 21 . Falleti, M. g., Sanfilippo, A., Maruff, P., Weih, L. y Phillips, K. A. (2005). The nature and severity of cognitive impairment associated with adjuvant chemotherapy in woman with breast cancer: A meta-analysis of the current literature. Brain and Cognition, 59, 60-70. [ Links ]
• 22. Fan, H. g., Houédé-Tchen, N., yi, Q-L, Chemerynsky, I., Downie, F. P., Sabate, K., Tannock, I. F. (2005). Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective controlled study. Journal of Clinical Oncology, 23, 8025-8032. [ Links ]
• 23. Fardell, J. E., Vardy, J., Logge, W. y Johnston, I. (2010). Single high dose treatment with methotrexate causes long-lasting cognitive dysfunction in laboratory rodents. Pharmacology, Biochemestry and Behaviour, 97, 333-339. [ Links ]
• 24. Feliú, J., López-Santiago, S., Martínez-Marín, V., Custodio, A. B. y Cruzado, J. A. (2011). Bases biológicas del deterioro de la función cognitiva inducido por los tratamientos antineoplásicos. Psicooncología, 8, 201-213. [ Links ]
• 25. Ferguson y Martison (2011). An overview of cognitive-behavioral management of memory dysfunction associated with chemotherapy. Psicooncologia, 8, 385-404. [ Links ]
• 26. Ferguson, R. J., McDonald, B. C., Saykin, A. J. y Ahles, T. A. (2007). Brain structure and function differences in monozygotic twins: possible effects of breast cancer chemotherapy. Journal Clinical Oncology, 25, 3866-3870. [ Links ]
• 27. Golden, C. J. TEA ediciones (2005). Stroop, Test de Colores y Palabras. Madrid: TEA Ediciones. [ Links ]
• 28. Gómez, F. (2011). Déficits neuropsicológicos asociados a alteraciones cerebrales secundarias a tratamientosoncológicos. Psicooncología, 8, 215-229. [ Links ]
• 29. Heflin, L. H., Meyerowitz, B. E., Hall, P., Lichtenstein, P., Pedersen, N. L. y gatz, M. (2005). Cancer as a risk factor for long-term cognitive deficits and dementia. Journal of the National Cancer Institute, 97, 854-856. [ Links ]
• 30 . Hermelink, K., Untch, M., Lux, M. P., Kreienberg, R., Beck, T., Bauerfeind, I.,Münzel, K. (2007). Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study. Cancer, 109,1905-1913. [ Links ]
• 31. Hurria, A., Gupta, S., Zauderer, M., Zuckerman, E. L., Cohen, H. J., Muss, H., Kornblith, A. B. (2005). Developing a cancer-specific geriatric assessment: A feasibility study. Cancer, 104, 1998-2005. [ Links ]
• 32. Hurria, A., Goldfarb, S., Rosen, C., Holland, J., Zuckerman, E., Lachs, M.S., Hudis, C. (2006). Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patient's perspective. Breast Cancer Research and Treatment, 98, 343-348. [ Links ]
• 33. Iconomou, G., Mega, V., Koutras, A., Iconomou, A. V. y Kalofonos, H. P. (2004). Prospective assessment of emotional distress, cognitive function, and quality of life in patients with cancer treated with chemotherapy. Cancer, 101, 404-411. [ Links ]
• 34. Jansen, C. E., Dodd, M., Miaskowski, C. A., Dowling, G. A. y Kramer, J. (2008). Preliminary results of a longitudinal study of changes in cognitive function in breast cancer patients undergoing chemotherapy with doxorubicin and cyclophosphamide. Psycho-Oncology, 17, 1189-1195. [ Links ]
• 35. Jansen, C. E., Miaskowski, C., Dodd, M., Dowling, G. y Kramer, J. A. (2005). A meta-analysis of studies of the effects of cancer chemotherapy on various domains of cognitive function. Cancer, 104, 2222-2233. [ Links ]
• 36. Jenkins, V., Shilling, V., Deustsch, G., Bloomfield, D., Morris, R., Allan, S., Winstanley, J. (2006). A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. British Journal of Cancer, 94, 828-834. [ Links ]
• 37. Jim, H. S. L., Donovan, K. A., Small, B. J., Andrykowski, M. A., Munster, P. N. y Jacobsen, P. B. (2009). Cognitive functioning in breast cancer survivors: A controlled comparison. Cancer, 115, 1776-1783. [ Links ]
• 38. Kohli, S., Griggs, J. J., Roscoe, J. A., Jean-Pierre, P., Bole, C., Mustian, K. M., Morrow, g. R. (2007). Self-reported cognitive impairment in patients with cancer. Journal of Oncology Practice, 3, 54-59. [ Links ]
• 39. Kreukels, B. P. C, Schagen, S. B., Ridderinkhof, K.R., Boogerd, W., Hamburger, H. L, Muller, M. J.,van Dam, F. S. (2006). Effects of high-dose and conventional-dose adjuvant chemotherapy on long-term cognitive sequelae in patients with breast cancer: An electrophysiologic study. Clinical Breast Cancer, 7, 67-68. [ Links ]
• 40. Kreukels, B. P. C., Hamburger, H. L., Ruiter, M. B., van Dam, F. S.A. M., Ridderinkhof, K. R., Boogerd, W., Schagen, S. B. (2008). ERP amplitude and latency in breast cancer survivors treated with adjuvant chemotherapy. Clinical Neurophysio-logy, 119, 533-341. [ Links ]
• 41. Lai, J. S., Butt, Z., Wagner, L., Sweet, J., Beaumont, J. Vardy, J., Cella, D. (2009). Evaluating the dimensionality of perceived cognitive function. Journal of Pain and Symptom Management, 37, 982-995. [ Links ]
• 42. López-Santiago, S. (2011). Estudio prospectivo del funcionamiento cognitivo en pacientes de cáncer de colon tratados con quimioterapia adyuvante. Tesis Doctoral para la obtención del título de Doctor en Psicología, Facultad de Psicología, Universidad Complutense de Madrid, Madrid, España. [ Links ]
• 43. López-Santiago, S., Cruzado, J. A. y Feliú, J. (2009). Deterioro cognitivo, estado emocional y calidad de vida en pacientes de cáncer de colon previamente a recibir tratamiento de quimioterapia. Psicooncología, 6, 121-137. [ Links ]
• 44. López-Santiago, S., Cruzado, J. A. y Feliú, J. (2011). Cremobrain. Revisión de estudios que evalúan el deterioro cognitivo de supervivientes de cáncer tratados con quimioterapia. Psicooncología, 8, 265-280. [ Links ]
• 45. López-Santiago, S., Cruzado, J. A., Custodio, A. B. y Feliú, J. (2011). Variables asociadas al deterioro cognitivo en pacientes de cáncer de colon. Psicooncología, 8, 301-314. [ Links ]
• 46. Matsuda, T., Takayama, R., Tashiro, M., Nakamura, y., Ohashi, y. y Shimozuma, K. (2005). Mild cognitive impairment after adjuvant chemotherapy in breast cancer patients - evaluation of appropriate research design and methodology to measure symptoms. Breast Cancer, 12, 279-287. [ Links ]
• 47. McAllister, T. W., Ahles, T. A., Saykin, A. J., Ferguson, R. J., McDonald, B. C., Lewis, L. D., Rhodes, C. H. (2004). Cognitive effects of cytotoxic cancer chemotherapy: Predisposing risk factors and potential treatments. Current Psychiatry Reports, 6, 364-371. [ Links ]
• 48. Mehlsen, M, Pedersen A. D., Jensen, A. B. y Zachariae, R. (2009). No indications of cognitive side-effects in a prospective study of breast cancer patients receiving adjuvant chemotherapy. Psycho-Oncology, 18, 248-257. [ Links ]
• 49. Mehnert, A., Scherwath, A., Schirmer, L., Schleimer,B., Petersen, C., Schulz-Kindermann, F., Koch, U. (2007). The association between neuropsychological impairment, self-perceived, cognitive deficits, fatigue and heath related quality of life in breast cancer survivors following standard adjuvant vs. high-dose chemotherapy. Patient Education and Counseling, 66, 108-118. [ Links ]
• 50. Mendoza, T. R., Wang, X. S., Cleeland, C. S., Morrisey, M., Johnson, B. A., Wendt, J. K., Huber, S. L. (1999). The rapid assessment of fatigue severity in cancer patients: Use of the Brief Fatigue Inventory. Cancer, 85, 1186-1196. [ Links ]
• 51. Meyers, C. A., Byrne, K. S. y Komaki, R. (1995). Cognitive deficits in patients with small cell lung cancer before and after chemotherapy. Lung Cancer, 12, 231-235. [ Links ]
• 52. Ordóñez, A., Feijoo, M. y González, M. (2006). Evaluación de la astenia. En M. González-Barón, M. A. Lacasta, A. Ordóñez (editores), Valoración clínica en el paciente con cáncer (pp. 79-87). Madrid: Médica Panamericana [ Links ] 53. Peña-Casanova J. (1990). Manual Test Barcelona Revisado Programa integrado de exposición neuropsicológica. Barcelona: Masson. [ Links ]
• 54. Peña-Casanova, J. (1991). Normalidad, semiología y patología neuropsicológicas: programa integrado de exploración neuropsicológica "Test Barcelona". Barcelona: Masson. [ Links ]
• 55. Peña-Casanova, J., gramunt, N. F. y Gich, J. F. (2004). Test neuropsicológicos. Fundamentos para una neuropsicología clínica basada en evidencias. Barcelona: Masson. [ Links ]
• 56. Phillips, K-A y Bernhard, J. (2003). Adjuvant breast cancer treatment and cognitive function: Current knowledge and research directions. Journal of the National Cancer Institute, 95 (3), 190-197. [ Links ]
• 57. Poon, M (2004). Trail Making Test en línea. Extraído el 7 de Julio, 2008. Disponible en http://www.angelfire.com/retro/michaelpoon168/trail_making_test.htm [ Links ] 58. Poppelreuter, M., Weis, J., Külz, A. K., Tucha, O., Lange, K. W. y Bartsch, H. H. (2004). Cognitive dysfunction and subjective complaints of cancer patients. European Journal of Cancer, 40, 43-49. [ Links ]
• 59. Reitan, R. M. (1958). Validity of the Trail Making Test as an indicator of organic brain damage. Perceptual and Motor Skills, 8, 271-276. [ Links ]
• 60. Rodin, M. B., Wallace, J. A., Lacy, M., Kuball, K., Pykkonen, B. y Freming, g. (2006). Does adjuvant chemotherapy (CT) exacerbate cognitive impairment in elderly breast cancer (BC) patients? Results of a prospective, longitudinal study Abstract. Journal of Clinical Oncology, 24, (20 Supplement): 10530. [ Links ]
• 61. Rubio, B., Sirgo, A., Forcadell, E., Mele, M. y Guma, J. (2009). Deterioro cognitivo inducido por los tratamientos oncológicos sistémicos en el cáncer de mama no metastático: revisión de estudios. Psicooncología, 6, 83-120. [ Links ]
• 62. Rugo, H. S. y Ahles, T. (2003). The impact of adjuvant therapy for breast cancer on cognitive function: current evidence and directions for research Abstract. Seminars in Oncology, 30, 749-762. [ Links ]
• 63. Ryan, E. L., Miskovitz, G., Sutton, D. y Ahles, T. (2011). A tailored occupational therapy approach to cognitive rehabilitation of chemotherapy-related cognitive side effects in breast cancer survivors:Two case studies of premenopausally affected women. Psicoonlogía, 8, 315-342. [ Links ]
• 64. Rzeski, W., Pruskil, S., Macke, A., Felderhoff-Mueser, U., Reiher, A. K., Hoerster, F., Ikonomidou, C. (2004). Anticancer agents are potent neurotoxins in vitro and in vivo. Annals of Neurology, 56, 351-360. [ Links ]
• 65. Sanz, A., Olivares, M. E. y Barcia, J. A. (2011). Aspectos Neuropsicológicos en pacientes diagnosticados de tumores cerebrales. Clínica y Salud, 22, 139-155. [ Links ]
• 66. Schagen, S. B., Boogerd, W., Muller, M. J., Huinink, W. T., Moonen, L., Meinhardt, W., van Dam, F. S. (2008). Cognitive complaints and cognitive impairment following BEP chemotherapy in patients with testicular cancer. Acta Oncológica, 47, 63-70. [ Links ]
• 67. Schagen, S. B. y van Dam, F. S. A. M. (2006). Does cognitive impairment after chemotherapy for breast cancer improve over time or does practice make perfect? Journal of Clinical Oncology, 24, 5170-5171. [ Links ]
• 68. Schagen, S. B, van Dam, F. S. A. M, Muller, M. J., Boogerd, W., Lindeboom, J. y Bruning, P. F. (1999). Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer, 85, 640-650. [ Links ]
• 69. Schagen, S. B., Muller, M. J., Boogerd W., Mellenbergh g. J. y van Dam F. S. A. M. (2006). Change in cognitive function after chemotherapy: A prospective longitudinal study in breast cancer patients. Journal of the National Cancer Institute, 98, 1742-1745. [ Links ]
• 70. Schagen, S. B, Muller, M. J., Boogerd, W., Rosenbrand, R. M., van Rhijn, D., Rodenhuis, S., van Dam, F. S. (2002). Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients. Annals of Oncology, 13, 1387-1397. [ Links ]
• 71. Shilling, V., Jenkins, V., Morris, R., Deutsch, G. y Bloomfield, D. (2005). The effects of adjuvant chemotherapy on cognition in women with breast cancer-preliminary results of an observational longitudinal study. The Breast, 14, 142-150. [ Links ]
• 72. Shilling, V., Jenkins, V. y Trapala, I.S. (2006). The (mis)classification of chemo-fog-methodological inconsistencies in the investigation of cognitive impairment after chemotherapy. Breast Cancer Research and Treatment, 95, 125-129. [ Links ]
• 73. Stewart, A., Bielajew, C., Collins, B., Parkinson, M. y Tomiak, E. (2006). A meta-analysis of the neuropsychological effects of adjuvant chemotherapy treatment in women treated for breast cancer. The Clinical Neuropsychologist, 20, 76-89. [ Links ]
• 74. Stewart, A., Collins, B., Mackenzie, J., Tomiak, E., Verma, S. y Bielajew, C. (2008). The cognitive effects of adjuvant chemotherapy in early stage breast cancer: a prospective study. Psycho-Oncology, 17, 122-130. [ Links ]
• 75. Scott, N. W., Fayers, P. M., Aaronson, N. K., Bottomley, A., de Graeff, A., Groenvold, M., Sprangers, M. A. G. (2008). EORTC QLQ-C30 Reference Values. Extraído el 1 Enero de 2009 del sitio Web: http://groups.eortc.be/qol/downloads/reference_values_manual2008.pdf [ Links ] 76. Tannock, I. F., Ahles, T. A., Ganz, P. A. y van Dam, F. S. (2004). Cognitive impairment associated with chemotherapy for cancer: Report of a Workshop. Journal of Clinical Oncology, 22, 2233-2239. [ Links ]
• 77. Tchen, N., Juffs, H. G., Downie, F. P., Yi, Q.-L., Hu, H. y Chemerynsky, I. (2003): Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. Journal of Clinical Oncology, 21, 4175-4183. [ Links ]
• 78. Tombaugh, T. N. (2004). Trail Making Test A and B: Normative data stratified by age and education. Archives of Clinical Neuropsychology, 19, 203-214. [ Links ]
• 79. Vardy, J. (2008). Neurocognitive effects of chemotherapy in adults. Australian Prescriber, 31, 22-24. [ Links ]
• 80. Vardy, J. (2009). Cognitive function in survivors of cancer. American Society of Clinical Oncology Educational, 1, 570-574. [ Links ]
• 81. Vardy, J. y Dhillon, H. (2010). The fog hasn't lifted on "chemobrain" yet: ongoing uncertainty regarding the effects of chemotherapy and breast cancer on cognition. Breast Cancer Research and Treatment, 123, 35-37. [ Links ]
• 82. Vardy, J., Rourke, S. y Tannock, I. F. (2007). Evaluation of cognitive function associated with chemotherapy: A review of published studies and recommendations for future research. Journal of Clinical Oncology, 25, 2455-2463. [ Links ]
• 83. Vardy, J. y Tannock, I. F. (2007). Cognitive function after chemotherapy in adults with solid tumours. Critical Reviews in Oncology/Hematology, 63, 183-202. [ Links ]
• 84. Vardy, J., Wefel, J. S., Ahles, T., Tannock, I. F. y Schagen, S.B. (2008). Cancer and cancer-therapy related cognitive dysfunction: An international perspective from the Venice cognitive workshop. Annals of Oncology, 19, 623-629. [ Links ]
• 85. Vardy, J., Wong, K., Yi, Q., Park, A., Maruff, P., Wagner, L., Tannock, I. F. (2006). Assessingcognitive function in cancer patients. Support Care Cancer, 14, 1111-1118. [ Links ]
• 86. Vardy, J. L., Xu, W., Booth, C. M., Park, A., Dodd, A., Rourke, S., Tannock, I. F. (2008). Relation between perceived cognitive function and neuropsychological performance in survivors of breast and colorectal cancer. Journal of Clinical Oncology, 26 (Supplement 15): 6016. [ Links ]
• 87. Wagner, L. I., Sweet, J. J., Butt, Z., Beaumont, J., Havlin, K. A., Sabatino, T., Cella, D. (2006). Trajectory of cognitive impairment during breast cancer treatment: a prospective analysis. Journal of Clinical Oncology, 24 (Supplement 20), 8500. [ Links ]
• 88. Wefel, J. S., Lenzi, R., Theriault, R. L., Davis, R. N. y Meyers, C.A. (2004). The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma. Cancer, 100, 2292-2299. [ Links ]
• 89. Wefel, J. S. y Meyers, C. A. (2005). Cancer as a risk factor for dementia: A house built on shifting sand. Journal of the National Cancer Institute, 97, 788-789. [ Links ]
• 90. Wefel, J. S., Saleeba, A. K., Buzdar, A. U. y Meyers, C.A. (2010). Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast caner. Cancer, 116, 3348-3356. [ Links ]
• 91. Wefel, J. S., Vidrine, D. J., Veramonti, T. L., Meyers, C. A., Marani, S. K., Hoekstra, H. J., gritz, E. R. (2011). Cognitive impairment in men with testicular cancer prior to adjuvant therapy. Cancer, 117, 190-196. [ Links ]
• 92. Weis, J., Poppelreuter, M., y Helge, H. (2011). Rehabilitation of therapy-related cognitive deficits in patients with breast cancer. Psicooncologia, 8, 371-384. [ Links ]
• 93. Zigmond, A. S. y Snaith, R. P. (1983). The Hospital Anxiety and Depression Scale. Acta Psychiatrica Scandinavica, 67, 361-370. [ Links ]